EP-027315

EP-027315 is an orally bioavailable, liver-targeted small molecule agonist of Toll-like receptor 7 (TLR7) developed by Enanta Pharmaceuticals for the treatment of chronic hepatitis B virus (HBV) infection. By selectively activating TLR7 on immune cells such as plasmacytoid dendritic cells, the drug induces the production of endogenous interferon-alpha and other proinflammatory cytokines within the liver environment. This localized immune stimulation is designed to suppress viral replication and enhance the clearance of HBV-infected hepatocytes, contributing to the goal of achieving a functional cure. The liver-targeted design of EP-027315 aims to maximize therapeutic efficacy while minimizing the systemic side effects typically associated with exogenous interferon therapies.